Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies

Current Opinion in Neurology

Volumn 29, Issue 5, 2016, Pages 572-580

  Goodfellow, John A ^a   Willison, Hugh J ^b  

^a QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Antibody; Ganglioside; Glycolipid; Neuropathy

Indexed keywords

ANTIBODY; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GM1 ANTIBODY; GANGLIOSIDE GQ 1B ANTIBODY; GLYCOLIPID; AUTOANTIBODY; GANGLIOSIDE;

ACUTE MOTOR AXONAL NEUROPATHY; ASSAY; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; METHODOLOGY; NEUROPATHY; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SENSITIVITY ANALYSIS; GUILLAIN BARRE SYNDROME; IMMUNOLOGY; PERIPHERAL NEUROPATHY;

AUTOANTIBODIES; GANGLIOSIDES; GLYCOLIPIDS; GUILLAIN-BARRE SYNDROME; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84978645301     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000361     Document Type: Review

References (60)

1. Willison HJ, Yuki N. Peripheral neuropathies and antiglycolipid antibodies. Brain 2002; 125:2591-2625.
2. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet 2016; http://dx.doi.org/10.1016/S0140-6736(16)00339-1. [Epub ahead of print]
3. Susuki K, Rasband MN, Tohyama K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007; 27:3956-3967.
4. Plomp JJ, Molenaar PC, O'Hanlon GM, et al. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol 1999; 45:189-199.
5. Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999; 45:168-173.
6. Goodfellow JA, Bowes T, Sheikh K, et al. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci 2005; 25:1620-1628.
7. Capasso M, Caporale CM, Pomilio F, et al. Acute motor conduction block neuropathy. Another Guillain-Barré syndrome variant. Neurology 2003; 61:617-622.
8. McGonical R, Rowan EG, Greenshields KN, et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 2010; 133:1944-1960.
9. Rajabally YA, Strens LH, Abbott RJ. Acute motor conduction block neuropathy followed by axonal degeneration and poor recovery. Neurology 2006; 66:287-288.
10. Cunningham ME, McGonigal R, Meehan GR, et al. Anti-ganglioside antibodies are removed from circulation in mice by neuronal endocytosis. Brain 2016; 139:1657-1665.
11. Lardone RD, Yuki N, Irazoqui FJ, Nores GA. Individual restriction of fine specificity variability in anti-GM1 antibodies associated with Guillain-Barré syndrome. Sci Rep 2016; 6:19901.
12. Cats EA, van der Pol WL, Tio-Gillen AP, et al. Clonality of anti-GM1 IgM antibodies in multifocal motor neuropathy and the Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2015; 86:502-504.
13. Kim JK, Bae JS, Kim DS, et al. Prevalence of antiganglioside antibodies and their clinical correlates with Guillain-Barré syndrome in Korea: a nationwide multicenter study. J Clin Neurol 2014; 10:94-100.
14. Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain-Barré syndrome: a critical revision and the need for an update. Clin Neurophysiol 2012; 123:1487-1495.
15. Mitsui Y, Kusunoki S, Arimura K, et al. A multicentre prospective study of Guillain-Barré syndrome in Japan: a focus on the incidence of subtypes. J Neurol Neurosurg Psychiatry 2015; 86:110-114.
16. Islam Z, Gilbert M, Mohammad QD, et al. Guillain-Barré syndrome-related Campylobacter jejuni in Bangladesh: ganglioside mimicry and cross-reactive antibodies. PLoS One 2012; 7:e43976.
17. Taheraghdam A, Pourkhanjar P, Talebi M, et al. Correlations between cytomegalovirus, Epstein-Barr virus, antiganglioside antibodies, electrodiagnostic findings and functional status in Guillain-Barré syndrome. Iran J Neurol 2014; 13:7-12.
18. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009; 32:150-163.
19. Koga M, Yuki N, Ariga T, et al. Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome? J Neuroimmunol 1998; 86:74-79.
20. Uysalol M, Tatli B, Uzel N, et al. A rare form of Guillain-Barré syndrome: a child diagnosed with anti-GD1a and anti-GD1b positive pharyngeal-cervical-brachial variant. Balkan Med J 2013; 30:337-341.
21. Lametery E, Dubois-Teklali F, Millet A, Manel V. Pharyngeal-cervical-brachial syndrome: a rare form of Guillain-Barré syndrome with severe acute bulbar palsy. Arch Pediatr 2016; 23:176-179.
22. Kim SY, Kim JK, Suh CK. Polycranial neuropathy and sensory ataxia with IgG anti-GD1a antibody as a variant of Guillain-Barré syndrome. J Clin Neurosci 2013; 20:473-475.
23. Guisset F, Ferreiro C, Voets S, et al. Anti-GQ1b antibody syndrome presenting as acute isolated bilateral ophthalmoplegia: report on two patients and review of the literature. Eur J Paediatr Neurol 2016; 20:439-443.
24. Kauser H, Jain P, Sharma S, Aneja S. Complete bilateral ophthalmoplegia with unilateral facial palsy in a child with anti-GQ1b syndrome. Indian J Pediatr 2015; 82:192-194.
25. Kajikawa S, Ohi T, Fugita A, Kusunoki S. A case of anti-GQ1b antibody syndrome associated with pure bilateral Adie's pupils. Brain Nerve 2016; 68:93-96.
26. Gupta G, Liu A. Atypical Miller Fisher syndrome with anisocoria and rapidly fluctuating papillary diameter. Case Rep Neurol Med 2015; 2015:472843.
27. Mori M, Kuwabara S, Koga M, et al. IgG anti-GQ1b positive acute ataxia without ophthalmoplegia. J Neurol Neurosurg Psychiatry 1999; 67:668-670.
28. Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol 2004; 148:200-205.
29. Sekiguchi Y, Mori M, Misawa S, et al. How often and when Fisher syndrome is overlapped by Guillain-Barré syndrome or Bickerstaff brainstem encephalitis? Eur J Neurol 2016; 23:1058-1063.
30. Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2014; 85:339-344.
31. Kim JK, Kim BJ, Shin KJ, et al. Acute bulbar palsy as a variant of Guillain-Barré syndrome. Neurology 2016; 86:742-747.
32. Garg N, Yuki N, Park SB, et al. Acute bulbar, neck and limb weakness with monospecific anti-GT1a antibody: a rare localized subtype of Guillain-Barré syndrome. Muscle Nerve 2016; 53:143-146.
33. O'Leary CP, Veitch J, Durward F, et al. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J Neurol Neurosurg Psychiatry 1997; 61:649-651.
34. Zhang M, Gilbert M, Yuki N, et al. Association of anti-GT1a antibodies with an outbreak of Guillain-Barré syndrome and analysis of ganglioside mimicry in an associated Campylobacter jejuni strain. PLoS One 2015; 10:e0131730.
35. Zhang M, Li Q, He L, et al. Association study between an outbreak of Guillain-Barré syndrome in Jilin, China, and preceding Campylobacter jejuni infection. Foodborne Pathog Dis 2010; 7:913-919.
36. Caudie C, Quittard Pinon A, Taravel D, et al. Preceding infections and antiganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barré syndrome patients. J Neurol 2011; 258:1958-1964.
37. Spagnoli C, Iodice A, Salerno GG, et al. CMV-associated axonal sensorymotor Guillain-Barré syndrome in a child: case report and review of the literature. Eur J Paediatr Neurol 2016; 20:168-175.
38. Vachalova I, Golden V, Heckmann JG. Anti-GM2,-GD1a and-GD1b positive purely isolated facial diplegia. Clin Neurol Neurosurg 2014; 122:131-132.
39. Smyth KA, Fritzler MJ, Kirton A. Acquired infantile abducens palsy associated with anti-GM2 antibodies. Pediatr Neurol 2011; 44:459-462.
40. Kishi M, Sakakibara R, Ogawa E, et al. Bilateral abducens palsy in a case of cytomegalovirus-associated Guillain-Barré syndrome. Neurol Sci 2011; 32:1219-1222.
41. Mehta A, Mahale R, Abhinandan KS, et al. Isolated acute bulbar palsy with anti-GM2 antibodies: a rare occurrence. Neurol India 2016; 64:331-334.
42. Rupp A, Galban-Horcajo F, Bianchi E, et al. Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis. J Peripher Nerv Syst 2013; 18:75-88.
43. O'Hanlon G, Veitch J, Gallardo E, et al. Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: clinical and immunopathological studies. Autoimmunity 2000; 32:133-144.
44. Kaida K, Morita D, Kanzaki M, et al. Ganglioside complexes as new target antigens in Guillain-Barré syndrome. Ann Neurol 2004; 56:567-571.
45. Kaida K, Kanzaki M, Morita D, et al. Antiganglioside complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 2006; 77:1043-1046.
46. Kaida K, Morita D, Kanzaki M, et al. Antiganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol 2007; 182:212-218.
47. Kaida K, Sonoo M, Ogawa G, et al. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barré syndrome. Neurology 2008; 71:1683-1690.
48. Greenshields KN, Halstead SK, Zitman FM, et al. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest 2009; 119:595-610.
49. Rinaldi S, Brennan KM, Willison HJ. Combinatorial glycoarray. Methods Mol Biol 2012; 808:413-423.
50. Galban-Horcajo F, Halstead SK, McGonigal R,Willison HJ. The application of glycosphingolipid arrays to autoantibody detection in neuroimmunological disorders. Curr Opin Chem Biol 2014; 18:78-86.
51. Delmont E, Robb H, Davidson A, et al. Prospective study comparing enzymelinked immunosorbent assay and glycoarray assay to detect antiglycolipid antibodies in a routine diagnostic neuroimmunology lab setting. Clin Exper Neuroimmunol 2015; 6:175-182.
52. Kuwahara M, Suzuki S, Takada K, Kusunoki S. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 2011; 239:87-90.
53. Shahrizaila N, Kokubun N, Sawai S, et al. Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes. Neurology 2014; 83:118-124.
54. Koga M, Gilbert M, Takahashi M, et al. GQ1b-seronegative Fisher syndrome: clinical features andnew serologicalmarkers. J Neurol 2012; 259:1366-1374.
55. Fukami Y, Wong AH, Funakoshi K, et al. Anti-GQ1b antibody syndrome: antiganglioside complex reactivity determines clinical spectrum. Eur J Neurol 2016; 23:320-326.
56. Rinaldi S, Brennan KM, Kalna G, et al. Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome. PLoS One 2013; 8:e82337.
57. Kornberg AJ, Pestronk A. Chronic motor neuropathies: diagnosis, therapy and pathogenesis. Ann Neurol 1995; 37 (Suppl 1):S43-S50.
58. Pestronk A, Choksi R, Blume G, Lopate G. Multifocal motor neuropathy: serum IgM binding to a GM1 ganglioside-containing lipid mixture but not to lipid alone. Neurology 1997; 48:1104-1106.
59. Nobile-Orazio E, Gianotta C, Briani C. Antiganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies. J Neuroimmunol 2010; 219:119-122.
60. Galban-Horcajo F, Fitzpatrick AM, Hutton AJ, et al. Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. Eur J Neurol 2013; 20:62-70.